Bio Green Med Solution
BGMS
13 hedge funds and large institutions have $300K invested in Bio Green Med Solution in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.
177,746% more capital inflows, than outflows
Capital inflows: $292K | Capital outflows: $164
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
44% more funds holding
Funds holding: 9 → 13 (+4)
34.7% more ownership
Funds ownership: 13.86% → 48.56% (+35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$251K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$20K |
| 3 |
Two Sigma Securities
New York
|
+$16.4K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$829 |
| 5 |
Archer Investment Corporation
Carmel,
Indiana
|
+$138 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
McIlrath & Eck
Arlington,
Washington
|
-$164 |
BGMS Hedge Fund Activity: Q4 2024 in Review
13 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Bio Green Med Solution (BGMS) for Q4 2024, worth a combined $300K — up 50% from $200K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BGMS positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, adding an estimated $251K. The largest seller was McIlrath & Eck, exiting entirely with an estimated $164 sold.
- 13 institutional investors held Bio Green Med Solution (BGMS) as of Q4 2024, up from 9 in Q3 2024.
- Funds reported $300K of Bio Green Med Solution stock for Q4 2024, up 50% quarter-over-quarter.
- 5 funds opened new Bio Green Med Solution positions in Q4 2024 and 1 closed out, a net change of +4 holders.
- The largest Bio Green Med Solution buyer in Q4 2024 was Armistice Capital, an estimated $251K added.
- The largest Bio Green Med Solution seller in Q4 2024 was McIlrath & Eck, an estimated $164 sold.
Based on aggregated 13F filings for Q4 2024.